Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
PLoS One ; 10(1): e0116535, 2015.
Article in English | MEDLINE | ID: mdl-25607548

ABSTRACT

The pathogenic role of inflammation and oxidative stress in chronic kidney disease (CKD) is well known. Anti-inflammatories and antioxidant drugs has demonstrated significant renoprotection in experimental nephropathies. Moreover, the inclusion of natural antioxidants derived from food and herbal extracts (such as polyphenols, curcumin and lycopene) as an adjuvant therapy for slowing CKD progression has been largely tested. Brazilian propolis is a honeybee product, whose anti-inflammatory, antimicrobial and antioxidant effects have been widely shown in models of sepsis, cancer, skin irritation and liver fibrosis. Furthermore, previous studies demonstrated that this compound promotes vasodilation and reduces hypertension. However, potential renoprotective effects of propolis in CKD have never been investigated. The aim of this study was to evaluate the effects of a subtype of Brazilian propolis, the Red Propolis (RP), in the 5/6 renal ablation model (Nx). Adult male Wistar rats underwent Nx and were divided into untreated (Nx) and RP-treated (Nx+RP) groups, after 30 days of surgery; when rats already exhibited marked hypertension and proteinuria. Animals were observed for 90 days from the surgery day, when Nx+RP group showed significant reduction of hypertension, proteinuria, serum creatinine retention, glomerulosclerosis, renal macrophage infiltration and oxidative stress, compared to age-matched untreated Nx rats, which worsened progressively over time. In conclusion, RP treatment attenuated hypertension and structural renal damage in Nx model. Reduction of renal inflammation and oxidative stress could be a plausible mechanism to explain this renoprotection.


Subject(s)
Anti-Inflammatory Agents/administration & dosage , Antioxidants/administration & dosage , Hypertension, Renal/drug therapy , Propolis/administration & dosage , Proteinuria/drug therapy , Animals , Anti-Inflammatory Agents/therapeutic use , Antioxidants/therapeutic use , Creatinine/blood , Disease Models, Animal , Hypertension, Renal/etiology , Kidney/drug effects , Kidney/pathology , Male , Nephrectomy , Propolis/therapeutic use , Proteinuria/etiology , Rats , Rats, Wistar , Renal Insufficiency, Chronic/prevention & control
2.
Am J Physiol Renal Physiol ; 305(2): F155-63, 2013 Jul 15.
Article in English | MEDLINE | ID: mdl-23657853

ABSTRACT

Adenine overload promotes intratubular crystal precipitation and interstitial nephritis. We showed recently that these abnormalities are strongly attenuated in mice knockout for Toll-like receptors-2, -4, MyD88, ASC, or caspase-1. We now investigated whether NF-κB activation also plays a pathogenic role in this model. Adult male Munich-Wistar rats were distributed among three groups: C (n = 17), receiving standard chow; ADE (n = 17), given adenine in the chow at 0.7% for 1 wk and 0.5% for 2 wk; and ADE + pyrrolidine dithiocarbamate (PDTC; n = 14), receiving adenine as above and the NF-κB inhibitor PDTC (120 mg·kg⁻¹·day⁻¹ in the drinking water). After 3 wk, widespread crystal deposition was seen in tubular lumina and in the renal interstitium, along with granuloma formation, collagen accumulation, intense tubulointerstitial proliferation, and increased interstitial expression of inflammatory mediators. Part of the crystals were segregated from tubular lumina by a newly formed cell layer and, at more advanced stages, appeared to be extruded to the interstitium. p65 nuclear translocation and IKK-α increased abundance indicated activation of the NF-κB system. PDTC treatment prevented p65 migration and normalized IKK-α, limited crystal shift to the interstitium, and strongly attenuated interstitial fibrosis/inflammation. These findings indicate that the complex inflammatory phenomena associated with this model depend, at least in part, on NF-κB activation, and suggest that the NF-κB system may become a therapeutic target in the treatment of chronic kidney disease.


Subject(s)
Adenine/analogs & derivatives , Inflammation Mediators/metabolism , NF-kappa B/metabolism , Nephritis, Interstitial/etiology , Nephrosclerosis/etiology , Pyrrolidines/therapeutic use , Thiocarbamates/therapeutic use , Adenine/adverse effects , Animals , Disease Models, Animal , Fibrosis , Granuloma/etiology , Inflammation Mediators/physiology , Kidney/pathology , Male , NF-kappa B/antagonists & inhibitors , Nephritis, Interstitial/metabolism , Nephritis, Interstitial/pathology , Nephrosclerosis/metabolism , Nephrosclerosis/pathology , Rats , Rats, Wistar
SELECTION OF CITATIONS
SEARCH DETAIL
...